Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration.
Sign Up to like & getrecommendations! Published in 2018 at "American journal of ophthalmology"
DOI: 10.1016/j.ajo.2018.04.008
Abstract: PURPOSE The Medicare cost savings from the use of bevacizumab in the United States for the treatment of exudative age-related macular degeneration (AMD) were estimated by replacing the use of bevacizumab with ranibizumab and aflibercept.… read more here.
Keywords: savings use; use bevacizumab; exudative age; treatment ... See more keywords